Why the study?
The prevalence of metabolic syndrome and cognitive impairment increases with age, with metabolic syndrome reducing overall cognition and cognitive impairment predicting drug-related problems.
Does suspected metabolic syndrome increase the risk of cognitive impairment in older adults receiving pharmaceutical care?
Population
Aging population receiving pharmaceutical care aged 60-74 vs 75+ years
Comparison
Presence vs absence of suspected metabolic syndrome (sMetS+ vs sMetS-)
Authors
Loading...
sMetS may link to cognitive impairment in pharmaceutical care recipients over 75; leaves open need for prospective screening trials.
Does suspected metabolic syndrome increase the risk of cognitive impairment in older adults receiving pharmaceutical care?
Suspected metabolic syndrome is associated with a higher prevalence of cognitive impairment in adults aged 75 and older.
Mačeková et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: